Re Conference

ReNeuron Group plc
06 December 2005





       ReNeuron to present at Harris Nesbitt healthcare conference


Guildford, UK, 6 December 2005: ReNeuron Group plc (LSE: RENE.L) today announces
that it will participate in the Harris Nesbitt 5th Annual Investor Conference:
Focus on Healthcare, scheduled for 8 December 2005 in New York City.  Michael
Hunt, Chief Executive Officer of ReNeuron, will give an overview of the
Company's activities and recent progress, and will participate in a panel
discussion focusing on the state of the art in stem cell-based medicine,
scheduled for 1:30pm EST on the day.



A webcast of the event will be available on ReNeuron's website at
www.reneuron.com, by clicking on the relevant links for this conference.




Enquiries:


ReNeuron
Michael Hunt, Chief Executive Officer                 Tel: [phone]


Financial Dynamics
Sarah Macleod                                        Tel: [phone]
Anna Keeble



Notes to Editors



ReNeuron is a leading, UK-based adult stem cell therapy business.  The Company
is applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.



ReNeuron has used its c-mycER(TAM) technology to generate genetically stable
neural stem cell lines.  This technology platform has multi-national patent
protection and is fully regulated by way of a chemically-induced safety switch.
Cell growth can therefore be completely arrested prior to in vivo implantation.



The Company's lead stem cell therapy, ReN001 for chronic stroke disability, is
in late pre-clinical development.  The Company plans to file for approval to
commence initial clinical trials in stroke by mid-2006, with trials commencing
as soon as possible thereafter.



In addition to its ReN001 stroke programme, ReNeuron has programmes to develop
stem cell therapies to address Huntington's disease, Parkinson's disease, Type 1
diabetes and diseases of the eye.



ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell range of cell lines for use in drug discovery applications
in the pharmaceutical industry.



The Company successfully completed its flotation on the London AIM market in
August 2005, raising £9.5million before expenses.  At flotation, the Company
also issued warrants which, if exercised, will raise a further £5.7m for the
Company by February 2007.  ReNeuron's shares are traded under the symbol RENE.L,
and its warrants are traded under the symbol RENW.L.



Further information on ReNeuron and its products can be found at
www.reneuron.com.



This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.





The terms 'ReNeuron' or 'the Company' refer to ReNeuron Group plc and its
subsidiary undertakings.




                      This information is provided by RNS
            The company news service from the London Stock Exchange